Literature DB >> 17013515

Liver cirrhosis and hepatic stellate cells.

Daniel Ferracioli Brandão1, Leandra Naira Zambelli Ramalho, Fernando Silva Ramalho, Sérgio Zucoloto, Ana de Lourdes Candolo Martinelli, Orlando de Castro e Silva.   

Abstract

The cirrhosis represents the final stage of several chronic hepatic diseases and it is characterized by the presence of fibrosis and morphologic conversion from the normal hepatic architecture into structurally abnormal nodules. In the evolution of the disease there is loss of the normal vascular relationship and portal hypertension. There are also regenerative hepatocellular alterations that become more prominent with the progression of the disease. The liver transplantation continues to be the only therapeutic option in cases of disease in terminal phase. The hepatic stellate cells (HSC) are perisinusoidal cells that store vitamin A and produce growth factors, citocins, prostaglandins and other bioactive substances. They can suffer an activation process that convert them to cells with a phenotype similar to myofibroblasts. When activated, they present increased capacity of proliferation, mobility, contractility and synthesis of collagen and other components of extracellular matrix. They possess cytoplasmic processes adhered to sinusoids and can affect the sinusoidal blood flow. HSC are important in pathogenesis of fibrosis and portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17013515     DOI: 10.1590/s0102-86502006000700013

Source DB:  PubMed          Journal:  Acta Cir Bras        ISSN: 0102-8650            Impact factor:   1.388


  9 in total

1.  MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide.

Authors:  Qing-Bing Wang; Yu Han; Ting-Ting Jiang; Wei-Min Chai; Ke-Min Chen; Bing-Ya Liu; Li-Fu Wang; Chunfu Zhang; Deng-Bin Wang
Journal:  Eur Radiol       Date:  2010-10-25       Impact factor: 5.315

2.  Effect of Kruppel-like factor 4 on Notch pathway in hepatic stellate cells.

Authors:  Yin-Kai Xue; Jun Tan; Dong-Wei Dou; Ding Chen; Lu-Jia Chen; Huan-Ping Ren; Li-Bo Chen; Xin-Gao Xiong; Hai Zheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

3.  Burn injury induces histopathological changes and cell proliferation in liver of rats.

Authors:  Jeferson André Bortolin; Hananiah Tardivo Quintana; Tabata de Carvalho Tomé; Flavia Andressa Pidone Ribeiro; Daniel Araki Ribeiro; Flavia de Oliveira
Journal:  World J Hepatol       Date:  2016-02-28

4.  Bone Marrow Stromal Cells Inhibit the Activation of Liver Cirrhotic Fat-Storing Cells via Adrenomedullin Secretion.

Authors:  Xiaodong Wang; Wei Zhao; Jinghua Wang; Kexin Shi; Xufu Qin; Qingfei Kong; Guangyou Wang; Lili Mu; Hulun Li; Bo Sun; Lijun Shi
Journal:  Dig Dis Sci       Date:  2014-12-02       Impact factor: 3.199

5.  TGF-beta and mesenchymal hepatic involvement after visceral leishmaniasis.

Authors:  Maria Irma Seixas Duarte; Heitor Franco de Andrade; Cleusa Fumica Hirata Takamura; Antonio Sesso; Felipe Francisco Tuon
Journal:  Parasitol Res       Date:  2008-12-05       Impact factor: 2.289

Review 6.  Retinyl ester hydrolases and their roles in vitamin A homeostasis.

Authors:  Renate Schreiber; Ulrike Taschler; Karina Preiss-Landl; Nuttaporn Wongsiriroj; Robert Zimmermann; Achim Lass
Journal:  Biochim Biophys Acta       Date:  2011-05-08

7.  Low concentrations of bilirubin inhibit activation of hepatic stellate cells in vitro.

Authors:  Yinhe Tang; Qiyu Zhang; Yefan Zhu; Gang Chen; Fuxiang Yu
Journal:  Mol Med Rep       Date:  2017-02-14       Impact factor: 2.952

Review 8.  Nanocarrier-mediated antioxidant delivery for liver diseases.

Authors:  Senlin Li; Huiru Li; Xiaoding Xu; Phei Er Saw; Lei Zhang
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

9.  Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.

Authors:  Lai Wei; Juan Yang; Min Wang; Sheng-Nan Xu; Hua-Min Liang; Qi Zhou
Journal:  Int J Mol Med       Date:  2014-08-19       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.